Open AccessPractical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer
Author(s) -
Sudeep Gupta,
Manish Kumar Singh,
Amish Vora,
Govind Babu,
Meenu Walia,
V Nautial,
Rajesh Saha,
B K Smruti,
Juhi Sharma,
Rakesh Koul,
Purvish M. Parikh,
Sandeep Aggarwal
Publication year - 2018
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/sajc.sajc_122_18
Subject(s) - medicine , breast cancer , tamoxifen , hormonal therapy , adjuvant , oncology , adjuvant therapy , hormone therapy , cancer , hormone , disease , stage (stratigraphy) , aromatase , gynecology , paleontology , biology
Optimization of adjuvant systemic therapy in women with early-stage hormone receptor-positive breast cancer includes the consideration of chemotherapy and duration of hormone therapy. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). Expert oncologist discussed on the duration of adjuvant hormonal therapy for improvement of OS and quality of life of breast cancer patients by providing reduction in recurrence and mortality. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.